Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells
Description
Supplementary data of the experiment: Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells.". Hepatocellular carcinoma (HCC) is a prevalent type of tumor. Given the controversy surrounding atorvastatin and HCC, we conducted this study to determine whether atorvastatin has anticancer activity against HCC.Methods: The impact of varying concentrations of atorvastatin (ATO) on the biological function of HCC cells was studied in vitro with high-throughput mRNA assays on cells.
Files
Steps to reproduce
MHCC-97H cells were treated with 40μM/L atorvastatin for 24 hours in vitro, and cells of the control and intervention groups were collected for high-throughput sequencing.C1-C3 was the control group, and T1-T3 was the atorvastatin intervention group.